Retinoids

DBCAT000355Therapeutic category

A group of tetraterpenes, with four terpene units joined head-to-tail. Biologically active members of this class are used clinically in the treatment of severe cystic ACNE; PSORIASIS; and other disorders of keratinization. A DrugBank category of 20 drugs. 11 of them are approved.

Also known as: Retinoic Acid Derivatives
Drugs: 13-cis-12-(3'-Carboxyphenyl)retinoic acid
4-Oxoretinol
Acitretin
Adapalene
Alitretinoin
Anhydrovitamin A
Bexarotene
Etretinate
Fenretinide
Isotretinoin
Motretinide
N-Ethylretinamide
Palovarotene
Ro 12-7310
Tazarotene
Transcrocetinate
Tretinoin
Trifarotene
Vitamin A
Zuretinol acetate

What you can answer from here — as of December 10, 2018

20DrugsEach linked to its full drug card

Listed above

44Drug targetsEvery drug–target pair in the class, with bond type

2,624Marketed productsAcross the regions we cover, with dosage forms and routes

10Routes of administrationHow the drugs in this class are given

Which targets do Retinoids share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account